CRISPR Therapeutics updates on CAR T pipeline; shifts focus to CTX112/CTX131, CTX110 Part B shows 23% 6-month CR

CRISPR Therapeutics AG

Next-generation candidates CTX112 (CD19) and CTX131 (CD70) incorporate knock-out of Regnase-1 and TGFBR2 to enhance potency.
Emerging data show CTX112 and CTX131 achieve significantly higher CAR T expansion and functional persistence in patients vs. first-gen.
CTX110 Phase 1/2 Part B reported increased 6-month complete response rate of 23%, up from 19% in Part A.
Company will transition CTX110 and CTX130 patients to long-term follow-up; CTX112 and CTX131 trials ongoing.
Internal GMP facility manufacturing CTX112 and CTX131 for clinical trials; manufacturing robustness improved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.